




RealRate

PHARMACEUTICAL 2024

PUMA Biotechnology INC
Rank 163 of 309



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of PUMA Biotechnology INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA Biotechnology INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 65% points. The greatest weakness of PUMA Biotechnology INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is 204%, being 9.5% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	156,185
Cost of Goods Sold	62,682
Intangible Assets	0
Liabilities, Current	99,382
Liabilities, Non-Current	72,693
Other Assets	73,488
Other Compr. Net Income	-4.0
Other Expenses	1,083
Other Liabilities	5,011
Other Net Income	-9,966
Other Revenues	235,637
Property and Equipment	855
Research and Development	50,382
Selling, General and Administrative Expense	89,933

Output Variable	Value in 1000 USD
Assets	230,528
Liabilities	177,086
Expenses	204,080
Revenues	235,637
Stockholders Equity	53,442
Net Income	21,591
Comprehensive Net Income	21,589
BaseVar	428,650
ECR before LimitedLiability	68%
Economic Capital Ratio	204%